---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-029588"
form_type: "8-K"
ticker: "AVBP"
cik: "0001868279"
company_name: "ArriVent BioPharma, Inc."
filed_at: "2026-03-17T23:59:59+00:00"
generated_at: "2026-05-15T10:56:43.052860+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ArriVent to present preclinical data on firmonertinib and ARR-002 at AACR 2026

## Summary
- Firmonertinib preclinical data shows high potency and brain penetrance; supports ongoing Phase 3 in EGFR ex20ins NSCLC.
- ARR-002 (MUC16/NaPi2b ADC) shows superior in vivo efficacy vs single-target ADCs in OVCAR-3 xenograft model.
- ARR-002 demonstrates favorable tolerability in cynomolgus monkeys with reversible hematologic findings.
- ARR-002 also selected for oral presentation at AACR Clinical Research Mini Symposium by Aarvik.

## SEC filing metadata
- accession: 0001104659-26-029588
- form_type: 8-K
- ticker: AVBP
- cik: 0001868279
- company_name: ArriVent BioPharma, Inc.
- filed_at: 2026-03-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1868279/000110465926029588/0001104659-26-029588-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1868279/000110465926029588/avbp-20260317x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-029588
- JSON: https://secwatch.observer/filing/0001104659-26-029588.json
- Plain text: https://secwatch.observer/filing/0001104659-26-029588.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.